

# CERTIFICATE

Survey of 24 June 2022

You have fulfilled the requirements of the External Quality Assessment with the following analysis

## Virus Genome Detection - Human Papilloma Viruses (373):

Validity 12 months:

Typing of "High Risk" HPV and "Low Risk" HPV (R: B3)

(R) analysis is subject to the RiliBÄK

**Participant:**  
41629  
Medyczne Laboratoria Diagnostyczne  
INVICTA Sp. z o.o.  
Polna 64  
81-740 Sopot

Düsseldorf, 18 July 2022



Prof. Dr. med. Michael Spannagl  
(Head of Reference Institution)



Prof. Dr. rer. nat. Heinz Zeichhardt  
(Adviser)

# CERTIFICATE OF PARTICIPATION

Survey of 24 June 2022

You have participated in the External Quality Assessment with the following analysis

## Virus Genome Detection - Human Papilloma Viruses (373):

Typing of "High Risk" HPV and "Low Risk" HPV (R: B3)

(R) analysis is subject to the RiliBÄK

**Participant:**  
41629  
Medyczne Laboratoria Diagnostyczne  
INVICTA Sp. z o.o.  
Polna 64  
81-740 Sopot

Düsseldorf, 18 July 2022



Prof. Dr. med. Michael Spannagl  
(Head of Reference Institution)



Prof. Dr. rer. nat. Heinz Zeichhardt  
(Adviser)